Molecule Structure

Scientific Name

Dasatinib

Description of the Drug

Dasatinib is a tyrosine kinase inhibitor used for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia.

Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01254

Brand Name(s)

Dasatinib, Sprycel

Company Owner(s)

Apotex Inc, Bristol Myers Squibb Co

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
Tyrosine-protein kinase ABL SINGLE PROTEIN INHIBITOR CHEMBL1862
Bcr/Abl fusion protein CHIMERIC PROTEIN INHIBITOR CHEMBL2096618
Stem cell growth factor receptor SINGLE PROTEIN INHIBITOR CHEMBL1936
Ephrin type-A receptor 2 SINGLE PROTEIN INHIBITOR CHEMBL2068
SRC PROTEIN FAMILY INHIBITOR CHEMBL2363074
Platelet-derived growth factor receptor beta SINGLE PROTEIN INHIBITOR CHEMBL1913

Unichem Links

Atlas Dasatinib
SureChEMBL SCHEMBL8226
PharmGKB PA162372878
Human Metabolome Database HMDB0015384
DrugBank DB01254
PubChem: Thomson Pharma 14859389
PubChem 3062316
LINCS LSM-1020
Nikkaji J2.086.852J
PDBe 1N1
BindingDB 13216
EPA CompTox Dashboard DTXSID4040979
DrugCentral 785
Brenda 5015
ChemicalBook CB4506696 CB81565483
Guide to Pharmacology 5678
rxnorm DASATINIB ANHYDROUS SPRYCEL DASATINIB
PubChem: Drugs of the Future 12015788
ChEBI 49375
ZINC ZINC000003986735